Nivalis Therapeutics

Nivalis Therapeutics, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of product candidates for patients with cystic fibrosis (CF). CF is a life-shortening genetic disease. Its lead product candidate is N91115, a small molecule that is in Phase II clinical trial, which addresses a defect in cystic fibrosis transmembrane conductance regulator (CFTR), resulting from mutations in the CFTR gene. The company was formerly known as N30 Pharmaceuticals, Inc. and changed its name to Nivalis Therapeutics, Inc. in February 2015. Nivalis Therapeutics, Inc. was founded in 2007 and is headquartered in Boulder, Colorado.
Boulder, US
29 (est)

Nivalis Therapeutics Locations

Boulder, US

Nivalis Therapeutics Metrics

Nivalis Therapeutics Summary

Founding Date


Market capitalization

$118 M

Closing share price


Nivalis Therapeutics Market Value History

Nivalis Therapeutics News

Nivalis Therapeutics Company Life